Corytuberine(Corytuberine) - 药物靶点：MCAT_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

MCAT

作用方式

抑制剂

作用机制

MCAT inhibitors(malonyl-CoA-acyl carrier protein transacylase inhibitors)

治疗领域

感染

在研适应症-

非在研适应症

幽门螺杆菌感染

原研机构

中国科学院

在研机构-

非在研机构

中国科学院

权益机构-

最高研发阶段无进展临床前

首次获批日期-

最高研发阶段(中国)无进展

特殊审评-

结构/序列

分子式C19H21NO4

InChIKeyWHFUDAOCYRYAKQ-LBPRGKRZSA-N

CAS号517-56-6

关联

100 项与 Corytuberine 相关的临床结果

登录后查看更多信息

100 项与 Corytuberine 相关的转化医学

登录后查看更多信息

100 项与 Corytuberine 相关的专利（医药）

登录后查看更多信息

105

项与 Corytuberine 相关的文献（医药）

2025-12-02·NATURAL PRODUCT RESEARCH

Anti-inflammatory and in silico docking studies of Litsea wightiana (Nees) Hook.f. (Lauraceae) leaf constituents

Article

作者: Rasmi, Avanoor Ramanathan ; Habeeba, Kalladi Ummu

Current study aimed to disclose the anti-inflammatory potential of the methanolic leaf extracts of L. wightiana (LWME). The in vitro studies focused on enzyme inhibition assays targeting the key enzymes such as cyclooxygenase, lipoxygenase and nitric oxide synthase and revealed that LWME effectively inhibited the activity of these enzymes. Gene expression studies confirmed the anti-inflammatory effect, demonstrating down regulation of genes associated with inflammation and key proinflammatory factors such as COX-2, TNF-α, IL-6 and NFkB. In vivo anti-inflammatory experiments by carrageenan-induced paw edoema method in model animals and inflammation was found to be reduced by 10% concentration of extract and significant at P˂0.001 level. GCMS and LCMS analysis were conducted and the resulted compounds were docked against target proteins indicated that most of the bioactive compounds showed better binding affinity with enzymes in which the dicentrinone showed higher affinity and it may be useful in the treatment of several ailments.

2025-09-26·CURRENT MEDICINAL CHEMISTRY

Exploring the Potential of Nuciferine in Diabetes Management via PTGS2 Pathway Targeting by Network Analysis and in Silico Modeling Approach

Article

作者: Margesan, Thirumal ; Sridevi, N.

Introduction::

Diabetes mellitus, a chronic metabolic disorder characterized by elevated blood glucose levels, has emerged as a significant global health burden. Chronic inflammation and insulin resistance are central to the pathogenesis of non-insulin- dependent (type 2) diabetes mellitus. PTGS2 (prostaglandin-endoperoxide synthase 2) has been implicated in inflammatory pathways associated with diabetic complications, making it a potential therapeutic target.

Methods::

Advanced computational methodologies were employed to identify potential natural compounds with anti-diabetic activity. Techniques included network pharmacology to establish compound-target-pathway relationships and in silico molecular docking to evaluate binding affinity and interaction profiles of selected phytochemicals with PTGS2.

Results::

PTGS2 and its downstream prostaglandin pathways were strongly associated with diabetic inflammation and insulin resistance. Molecular docking identified Corytuberine and Nuciferine as having high binding affinities with PTGS2. Network pharmacology analysis confirmed Nuciferine’s connection to PTGS2, supporting its role as a bioactive agent targeting diabetes-related inflammatory processes.

Discussion::

The findings suggest that PTGS2 contributes to the progression of insulin resistance and chronic inflammation in type 2 diabetes. Targeting this enzyme with bioactive compounds such as Nuciferine may offer therapeutic benefits. However, translational studies and clinical trials are essential to validate these computational predictions and assess safety and efficacy in vivo.

Conclusion::

Nuciferine exhibits promising potential in modulating PTGS2 activity and improving insulin sensitivity. Continued research and clinical validation are needed to confirm its efficacy and support the development of novel anti-diabetic therapies targeting inflammatory pathways.

conclusion::

Ongoing research is crucial for validating Nuciferine efficacy and signaling innovative treatment strategies by targeting PTGS2.

2025-06-01·FITOTERAPIA

Brunodelphinone and Brunodelphinine a, two novel C20-diterpenoid alkaloids isolated from Delphinium brunonianum Royle

Article

作者: Zhu, Chen-Chen ; Liu, Fang-le ; Lin, Chao-Zhan ; Dawa, Ze-Ren ; Wang, Mei-Qi ; Zou, Yuan-Sheng

A novel htisine-type C₂₀-diterpene alkaloid with a benzoate skeleton Brunodelphinone (1), a novel htisine-type C₂₀-diterpenoid alkaloid Brunodelphinine A (2), along with seven known diterpenoid alkaloids (3-9), four aporphinoid alkaloids (10-13), one β-Carboline alkaloid (14), and four flavonoid glycosides (15-18), were isolated from Delphinium brunonianum Royle. Their structures were elucidated by extensive spectroscopic analyses (including 1D and 2D-NMR, HR-ESI-MS, and single-crystal X-ray diffraction analyses). The lipid-lowering and anti-inflammatory activities of compounds were evaluated using the FFA-induced lipid accumulation in mouse primary hepatocytes (MPHs). Compound 2 significantly alleviated the FFA-induced lipid accumulation and suppressed the levels of ALT, TNF-α, and IL-6 in MPHs.

100 项与 Corytuberine 相关的药物交易

登录后查看更多信息